We know most people who develop severe disease often don’t develop those symptoms until the second week of infection,but so far hospitals are not being overwhelmed and,if symptoms are resolving quickly,it does raise hope that this variant may cause a more benign infection than Delta.
We also can’t yet tell if this is a transmission threat of the same proportion in settings outside southern Africa. Most cases to date have been reported in South Africa which has low vaccination coverage with only 25 per cent of the population fully vaccinated,and rates are even lower in neighbouring countries. There are also higher numbers of immunocompromised people living with HIV/AIDS.
The virus has already spread beyond the southern African countries with cases among arrivals from the region now reported in Sydney,as well as in Belgium,Hong Kong and Italy. Omicron is also suspected to be the variant responsible for at least some of the 61 positive detections among arrivals on two recent flights from Johannesburg to the Netherlands.
Two cases have also been reported in Britain,one in Essex and another in Nottingham,both linked to travel to southern Africa. At this stage,we have no reports of local transmission outside southern Africa,but it may only be a matter of time as some countries have not had border testing requirements in place for international arrivals in recent times,only reinstating these now.
One of the signals that a new variant may be of concern is if testing methods do not perform as well. The good news is that PCR testing still works for Omicron and,in fact,it seems certain PCR tests can even screen for this variant. This has been used in South Africa to estimate that 90 per cent of COVID-19 cases are caused by this variant even though only small portion has been genetically confirmed so far.
If countries around the world can also use the PCR test to identify possible incursions of this variant at the time of the first test result,it will help enormously to track and control this variant. It also enables detection in regions where genomic testing is less accessible or will take a long time,including resource-poor countries.